Abstract
The aim of this study was to examine the impact of kolaviron on cyclooxygenase, thromboxane A2 activity, lipid peroxidation and lactate dehydrogenase level in dexamethasone treated Wistar rats. Twenty (20) male Wistar rats weighing between 150 g and 200 g were randomly selected into four groups containing five rats each. Control rats received standard feed and water. Group two received 3 mg/kg body weight of dexamethasone intraperitoneally every two days for 9 days. Group 3 received 3 mg/kg body weight of dexamethasone intraperitoneally every two days for 9 days plus daily oral administration of 100 mg/kg of kolaviron for 30 days. Results showed that there was no effect of dexamethasone and kolaviron on COX and THX-A 2 in all the groups. Dexamethasone increased MDA concentration, TG, VLDL, LDL, urea and creatinine but decreased serum LDH and HDL without altering the total cholesterol(TC) and superoxide dismutase (SOD) enzyme, decreased catalase activity and distorted cellular integrity of the liver, kidney and aorta. Treatment with kolaviron positively reversed the distorted lipid profile and peroxidation and improved catalase and SOD activity. Lactate dehydrogenase activity was significantly ( p <0.01) decreased in the dexamethasone and further lowered upon treatment with kolaviron when compared to the DEX group. It is concluded that dexamethasone does not affect cyclooxygenase and thromboxane activity but potentiates lipid peroxidation with some cellular distortion. Kolaviron does not alter Cox activity, protect against lipid peroxidation, cellular integrity and is hypolipidemic.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
